Should I buy, hold, or sell NIVF stock right now?

NewGenIvf Group Limited (Class A) (NIVF) currently earns a Roarable Rating of E (Strong Sell — SELL) with 20/100 RQD Confidence. Stretched risk/reward at current multiples (-33% return on capital) under elevated 10-year interest-rate pressure.

What is NIVF's 12-month price target and RQD AI Jury consensus?

NIVF's 12-month base price target is $0.81 (range $0.63 to $21954.24), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Stock Ratings / Health Care / NIVF

MGRX (28) CCEL (70) PARK (60) VMD (72) ⌘ Pro Terminal →

NewGenIvf Group Limited (Class A) (NIVF) — RQD Stock Rating Cockpit

$0.98 -14.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.95

NewGenIvf Group Limited (Class A) (NIVF) carries a Roarable Rating of E (Strong Sell) with 20/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $9.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NIVF Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NIVF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, NewGenIvf Group Limited (Class A) (NASDAQ: NIVF) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $0.98 (-14.05% 1D, market cap $9.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 4/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NIVF ranks #985 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NIVF compare to MGRX and CCEL in the Health Care sector?

▼

Within the Health Care sector (Misc Health and Biotechnology Services), NIVF carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.8%. By comparison, MGRX (Mangoceuticals Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $5.2M) and CCEL (Cryo-Cell International Inc.) posts a B- grade (70/100 RQD, P/E N/A, ROIC 18.2%, cap $42.0M). Among the 5-stock peer group, VMD leads on earnings multiple (24.6x) while CCEL leads on capital efficiency (18.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NIVF?

▼

Per NIVF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001981662), NewGenIvf Group Limited (Class A) generated $4.7M in revenue (-13.0% YoY), $9.9M in net income, and -$11.1M in free cash flow against $32.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.95 (-2.72%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (20/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-17.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NIVF)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (20/100 Composite)

🔍 WHY NIVF SCORES 20/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+7/20 pts (35% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 23.2 (OVERSOLD (<32))

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+5/20 pts (25% of score)

SEC Form 4 / 13F Thermometer: 25% Net Buy • Disciplined Float (+0.72% YoY Shares)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk4/20 pts (-16 pt drag)

Balance-sheet & 10-K footnote risk deducts 16 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.56+28.2% Next Q

Q2 (-2Q)

Grade E$2.00-42.5% Next Q

Q3 (-1Q)

Grade E$1.15-14.8% Next Q

Current

Grade E$0.98-11.8% Hist 90D α

Trajectory: E (28) → E (20)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NIVF Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NIVF currently carries a cautious 20/100 (E) rating due to SEC 10-K Forensic Risk (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($16.41) and Max Pain ($1.03) forces dealer call-delta covering toward $21,954.24.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NIVF• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NIVF Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 20%NO 80%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

23.230 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.63>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $1$0.98H: $20,909

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 1 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 11 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on NIVF

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (15)

-32.8% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (20)

Altman-Z 0.63 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (25)

8/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like NIVF

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NIVF)

✓Walkthrough of NIVF's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NIVF // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -99.80%🛡️ HOLDING TREND SUPPORT

2026-11-03O $1.14H $1.14L $0.98C $0.98VOL 169.5K

SUP: $-13.59SMA50: $16.41SMA200: $378.0

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NIVF Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NIVF Butterfly Map → + Track NIVF →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -13.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NIVF today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NIVF. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NIVF today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NIVF)

Health Care Rank #985 of 1015 ⚔️ MGRX vs NIVF Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NIVF vs. MGRX, CCEL, PARK, VMD)

Industry: Misc Health and Biotechnology Services (10 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, NewGenIvf Group Limited (Class A) (NIVF) ranks #985 by composite RQD confidence (20/100, grade E) and #895 by equity capitalization ($9.7M). Within this direct 5-issuer industry benchmark cohort, VMD leads on earnings valuation at 24.6x trailing P/E, while CCEL leads on capital efficiency and profitability with 18.2% ROIC and — gross margin. VMD currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with NIVF at 20/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NIVF ACTIVE NewGenIvf Group Limited (Class A)	E	20/100	—	—	-32.8%	-14.05%	$9.7M	Benchmark Subject
MGRX Mangoceuticals Inc.	E	28/100	—	54.9%	-35.0%	-8.22%	$5.2M	/mgrx-vs-nivf →
CCEL Cryo-Cell International Inc.	B-	70/100	—	—	18.2%	+0.48%	$42.0M	/ccel-vs-nivf →
PARK Park Dental Partners Inc.	C-	60/100	—	—	—	+5.14%	$100.3M	/park-vs-nivf →
VMD Viemed Healthcare Inc.	B	72/100	24.6x	57.5%	13.0%	-2.81%	$368.3M	/vmd-vs-nivf →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001981662 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), NewGenIvf Group Limited (Class A) (NIVF) reported GAAP revenue of $4.7M (-13.0% vs. FY2024 revenue of $5.4M , and -8.0% cumulative change since FY2023) , GAAP net income of $9.9M, operating cash flow of -$10.9M, and free cash flow of -$11.1M (-33.0% YoY). On the balance sheet, NIVF closed FY2025 with $32.7M in total assets against $0 in total debt (Altman Z-Score: 0.63, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$4.7M	$9.9M	-$10.9M	-$11.1M	$32.7M	—
FY2024 (FY)	2024-12-31	$5.4M	-$524.6K	-$8.3M	-$8.3M	$3.6M	—
FY2023 (FY)	2023-12-31	$5.1M	$130.2K	-$1.8M	-$1.8M	—	—

3. NIVF Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NIVF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NIVF compare to MGRX and CCEL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NIVF?

Where is NIVF trading relative to its 50-day, 200-day, and 52-week technical levels?

NIVF last traded at $0.98 (-14.05% on volume of 169,540 shares), positioning the stock -94.03% below its 50-day simple moving average ($16.41) and -99.74% below its 200-day simple moving average ($378.03). Across its 52-week range of $0.96 to $20,908.80, NIVF sits at the 0.0% percentile with a 14-day RSI of 23.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.10).

Direct Sub-Reports: NIVF RQD Cockpit NIVF 12M Forecast NIVF Earnings & Move NIVF Dividends & DRIP NIVF Insiders & 13F NIVF Whale Options NIVF Profit Sankey NIVF News & Why

ROARABLE RATING BRIEF • RQD 20/100 (E) ✓ SEC XBRL & RQD VERIFIED

NIVF — NewGenIvf Group Limited (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

NewGenIvf Group Limited (Class A) (NIVF) earns a live Roarable RQD composite score of 20/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.98 (-14.05% 1D, market capitalization $9.7M).

Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -32.8%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (7/20) + Forensic Balance Sheet (4/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.63, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

NewGenIvf Group Limited (Class A) (NIVF) is a NASDAQ-listed operating company in the Misc Health and Biotechnology Services industry (Health Care sector) with an equity market capitalization of $9.7M. The business operates with a gross margin of 0%, an operating margin of -60%, and a return on invested capital (ROIC) of -32.8% (free cash flow yield of 0%). Within the Misc Health and Biotechnology Services peer group, investor evaluation centers on operating leverage, unit margin durability, and capital allocation efficiency across market cycles.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), NewGenIvf Group Limited (Class A) (NIVF) reported $4.7M in annual revenue (up from $5.4M in FY2024, -13.0% YoY) and $9.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($5.1M revenue, $130.2K net income) through FY2025, NIVF scaled operating cash flow to -$10.9M and free cash flow to -$11.1M, backed by $32.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 20/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.96 – $20,908.80 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for upstream dependencies, downstream customers, or sector correlations. A prospective investor should monitor whether future filings identify concentrated dependencies, since the absence of mapped links means no second-order ripples can be evaluated from the supplied data.

Key Question #1: Can NIVF sustain or expand its -60.0% operating margin and -32.8% ROIC against Misc Health and Biotechnology Services peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $4.7M and free cash flow of -$11.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is NIVF's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NIVF Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for NewGenIvf Group Limited (Class A) (NIVF) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NIVF Debate Forum (3) ↓

🟡 MARKET WIRE Simply Wall St • 22h ago

NewGenIvf Group (Nasdaq:NIVF) - Stock Analysis

Simply Wall St report covering NewGenIvf Group Limited (Class A) (NIVF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 12d ago

Premarket movers Oct. 22: double-digit gainers and losers

Oct. 22 premarket movers featured double-digit percentage changes, led by SABSW up 83.72% among gainers and TWG down 29.04% among losers.

Read Full Source ↗

🔴 RISK WATCH Benzinga • 12d ago

Why QuantumScape Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket

QuantumScape rises 9.1% after narrower loss and new solid-state battery production plans; SHFS leads gainers while POM and others fall premarket.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 12d ago

Top Movers: US Session Features Double-Digit Gainers and Losers

US session top movers include SVRN and XHLD among gainers, while PRSO and WORX lead losers, each with double-digit percentage changes.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 12d ago

Top US Stock Movers: Today's Gainers and Losers

Today's US session top movers include SDEV up 62.64%, SHFS up 59.07%, and CJMB down 36.36%, with AHT and AMOD among gainers on company news.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 12d ago

Gap Movers for Oct. 21, 2026: Upside and Downside Stocks

Oct. 21, 2026 gap list: SHFS and SPHL led gap-up movers, while CJMB and TKNO led gap-down movers in a session split between sharp upside and downside moves.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 13d ago

Premarket Movers on Oct. 21, 2026: Gainers and Losers

Premarket movers for Oct. 21, 2026, included SHFS, OLOX and AHT among gainers, while TKNO, HKPD and NIVF were among the session's losers.

Read Full Source ↗

🟢 CATALYST Benzinga • 18d ago

Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Alcoa shares rose after Q3 earnings beat estimates; Rubico and others surged, while Nuburu, Jaguar Health and other stocks fell premarket.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NIVF Bull vs. Bear Conversation Board — What's Your Call at $0.98?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NIVF 🐻 33% BEARISH CONVICTION

MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $1.24 (+26.5%)

📌 Pinned Debate

Revenue of $4.7M in FY 2025 and a reported net margin of 68% show that some reported earnings activity exists despite operating losses.

Revenue of $4.7M in FY 2025 and a reported net margin of 68% show that some reported earnings activity exists despite operating losses.. When you look under the hood at NIVF, Fundamental Cash Engine is 1/20 with 0.0% gross margins and -32.8% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $20908.80. My 12M target is $1.24.

SectorRotator 🐂 BULL

@MacroHawk_NYC Agree on the RQD 20/100 quality, though with 1.0 beta I'm scaling in with half-size at $0.98 and keeping dry powder in case we test $0.91.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $0.77 (-21.4%)

Spot @ $0.98

A 1/20 Fundamental Cash Engine score, ROIC of -32.8%, FCF of -$11.1M against $0.8M of cash, and an Altman Z of 0.63 point to a high pro

Fading this rally in NIVF at $0.98. A 1/20 Fundamental Cash Engine score, ROIC of -32.8%, FCF of -$11.1M against $0.8M of cash, and an Altman Z of 0.63 point to a high probability of financial distress.. With a beta of 1.0 and the stock sitting at $0.98 (52-wk range $0.96–$20908.80), the easy multiple expansion is already priced in.